Business
ADMISSION TO TRADING ON AIM & FIRST DAY DEALINGS
ADMISSION TO TRADING ON AIM & FIRST DAY DEALINGS.
About this update from Abingdon Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6282I\n Abingdon Health PLC\n 15 December 2020\n \n \n \n \n NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT\n \n \n \n \n \n 15 December 2020\n \n \n \n \n ABINGDON HEALTH PLC\n (\"Abingdon Health\" or the \"Company\")\n ADMISSION TO TRADING ON AIM AND FIRST DAY OF DEALINGS\n Abingdon Health plc, a lateral flow diagnostics company providing contract service solutions to a global client base in the healthcare sector and other industries, is pleased to announce the admission of its entire issued and to be issued ordinary share capital to trading on the AIM market of the London Stock Exchange (\"Admission\"). Dealings in the ordinary shares of the Company will commence today at 8.00 a.m. under the ticker \"ABDX\" and the ISIN \"GB00BLF79J41\".\n The Company has successfully raised £22 million (before expenses) by way of a placing of 22,916,666 ordinary shares of 0.025 pence each (\"Ordinary Shares\") with institutional investors at a price of 96.0 pence per Ordinary Share (the \"Placing Price\"). Abingdon Health's market capitalisation at the Placing Price on admission will be approximately £92 million. N+1 Singer is acting as Sole Broker and Nominated Adviser in relation to Admission.\n The Company's admission document is available to view on its website at: www.abingdonhealth.com\n \n Chris Yates, Chief Executive Officer of Abingdon Health, commented:\n \"We are pleased to have achieved this important milestone and to be making our debut on the AIM market of the London Stock Exchange today. The money raised will, amongst other things, enable us to scale up our manufacturing in order to meet the demand for our AbC-19TM rapid lateral-flow test and allow us to further establish our global commercial and operational footprint. I would personally like to thank our new and existing investors for their support, and our dedicated staff for their hard work and diligence. We are looking forward to this next exciting chapter in Abingdon Health's development.\"\n \n \n Mark Wyatt, Investment Director for Mercia*, said:\n \"It has been a pleasure working with the experienced team at Abingdo...